來自擴(kuò)大臨床試驗(yàn)的資料顯示：設(shè)計(jì)用于肺癌診斷的檢測試劑盒敏感性和特異性極高。這些資料在2005年5月費(fèi)城舉行的世界生物標(biāo)志物大會上進(jìn)行了報(bào)道。

CellCorrect LAb檢測試劑盒是由CeMines公司(Golden, CO, USA)研制開發(fā)的。最新資料還證實(shí)了在乳腺、結(jié)腸和胃癌患者血液中存在具有診斷意義的自身抗體。該公司宣布完成了涉及轉(zhuǎn)錄機(jī)制分子的設(shè)計(jì)與傳輸?shù)膬身?xiàng)申請。CeMines相信這種知識產(chǎn)權(quán)將對該公司研制開發(fā)不同類型癌癥治療方法中發(fā)揮重要作用。

CellCorrect LAb檢測自身免疫的改變和血液中疾病相關(guān)的自身抗體模式。CellMines公司聲稱，更進(jìn)一步的研究證實(shí)作為鑒別癌癥的生物標(biāo)志物的特定抗體具有特異性和一致性， 能夠作為癌癥的診斷檢測試驗(yàn)。該公司使用具有產(chǎn)權(quán)的生物資訊為基礎(chǔ)的統(tǒng)計(jì)模式識別應(yīng)用軟件，叫做“分子指紋”軟件，該軟件能夠評估癌癥患者中特定抗體模式。
 
Detection Kit to Aid Diagnosis of Lung Cancer
 
New data from an expanded comprehensive clinical study have demonstrated high sensitivity and specificity of a detection kit designed for the diagnosis of lung cancer. The data were presented at the World Biomarker Congress in May 2005 in Philadelphia (PA, USA).

The CellCorrect LAb detection kit was developed by CeMines, Inc. (Golden, CO, USA). The updated data also demonstrated the presence of diagnostically informative autoantibodies in the blood of breast, colon, and stomach cancer patients. The company has announced the filing of two patents claiming specific design and delivery of molecules that interfere with transcriptional mechanisms. CeMines believes this intellectual property will play a key role in the company’s development of drugs to treat different types of cancer.

CellCorrect LAb detects altered autoimmunity and associated patterns of disease-related autoantibodies in the bloodstream. Extensive studies have demonstrated that specific and consistent patterns of certain antibodies have regularly proven their utility as composite biomarkers to characterize cancer, states CeMines, and can therefore be used as diagnostic tests for cancer. The company uses a proprietary bioinformatics-based statistical pattern-recognition application called Molecular Fingerprinting, which evaluates the patterns of certain antibodies in the profiles of cancer patients.